Data Mining of the US FDA’s Adverse Events Reporting System Database to Evaluate Drug–Drug Interactions Associated with Statin-Induced Rhabdomyolysis

Background and Objective With the rise in polypharmacy, it is increasingly important to identify drug–drug interactions (DDIs) that cause serious adverse events in a timely manner. The purpose of the study was to investigate the utility of systematic data mining of the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database for interactions between statins (HMG-CoA reductase inhibitors) and other drugs that underlie a higher risk for rhabdomyolysis.